|
Press Releases |
|
|
|
Friday, August 25, 2023 |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
Tuesday, June 7, 2022 |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
Friday, May 13, 2022 |
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
Thursday, March 17, 2022 |
|
Hua Medicine Announces 2021 Annual Results |
Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
Sunday, September 26, 2021 |
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
Wednesday, September 15, 2021 |
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
Thursday, August 19, 2021 |
|
Hua Medicine Announces 2021 Interim Results |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
Friday, April 23, 2021 |
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
Friday, March 19, 2021 |
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase
Apr 25, 2024 21:00 HKT/SGT
|
|
|
Black Spade Donates Art and Jewellery Collection To Hong Kong Red Cross
Apr 25, 2024 20:40 HKT/SGT
|
|
|
Q2 Metals Announces Assay Results from Its 2023 Inaugural Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada
Apr 25, 2024 19:09 HKT/SGT
|
|
|
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
|
|
|
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
|
|
|
8 in 10 Singapore businesses experienced more change in last 4 years than previous two decades: HubSpot Research
Apr 25, 2024 16:00 HKT/SGT
|
|
|
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
|
|
|
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
|
|
|
CITIC Telecom CPC Becomes New VMware Cloud Service Provider Pinnacle Tier Partner in the Broadcom Advantage Partner Program
Apr 25, 2024 13:07 HKT/SGT
|
|
|
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
|
|
|
Elevate Your Sleep Game This World Health Day with LAC
Apr 25, 2024 09:00 HKT/SGT
|
|
|
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 9:00 JST
|
|
|
GA-ASI Selected to Build CCA for AFLCMC
Apr 25, 2024 07:00 HKT/SGT
|
|
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 25, 2024 01:47 HKT/SGT
|
|
|
The South China Sea: A Nuanced Understanding Required
Apr 24, 2024 21:12 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|